Treatment of Osteomyelitis-associated Pressure Ulcers by Surgical Flaps and Anti-bacterial Agents
Study Details
Study Description
Brief Summary
People with neuromotor disability (i.e. following an inborn or acquired spinal cord, cerebral or peripheral neurological lesion) are at high risk of osteomyelitis-associated pressure ulcers.
The management of osteomyelitis-associated pressure ulcers is controversial. In our center, patients benefit from a one stage surgical management with bone shaving and flap covering osteitis of pressure ulcer to perform wound closing. Surgery is followed by an antibiotic treatment, secondarily adapted to intraoperative samples.
The aim of this study is to describe the cohort and to identify factors associated with failure (or success) in this frail population.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
This is a prospective, monocentric, cohort study of neurological disabled inpatients subjects treated in the perioperative disability unit (UPOH) of our university hospital for osteomyelitis-associated pressure ulcer by surgical flaps and anti bacterial agents.
All eligible inpatient subjects with neuromotor disability and admitted for the treatment of osteomyelitis-associated pressure ulcers by surgical flaps will be consecutively included.
Data will be collected from the patients' medical records, in particular data related to their clinical, radiological, biological, and physiological examinations. Data related to sitting, nutrition, spasticity, bladder and bowel disorders, bacteriological sampling and antibiotic treatments will be collected.
This is a routine care study; no procedures are added for research purposes. It is an ancillary study to the NO-AGING study.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Subjects with osteomyelitis-associated pressure ulcers Subjects with neuromotor disability and admitted for the treatment of osteomyelitis-associated pressure ulcers |
Other: Surgical flap and anti-bacterial agents
Surgical flap and anti-bacterial agents
|
Outcome Measures
Primary Outcome Measures
- Success at 30-45 days after surgery [30-45 days after surgery (depening on the surgical technique)]
Success is defined as the absence of surgical revision, the absence of additional antibiotic therapy, and the absence of inflammatory signs or deep disunion of more than 2 cm.
Secondary Outcome Measures
- Success at 12 months after surgery [12 months after surgery]
Success is defined as the absence of surgical revision, the absence of additional antibiotic therapy, and the absence of inflammatory signs or deep disunion of more than 2 cm.
- Description of the patients' bacteriological tests [Through hospital admission, up to 7 days after surgery]
Intraoperative samples and drain samples.
- Death [12 months after surgery]
Obtained from the INSEE database.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients >= 18 years old ;
-
Treated in the Perioperative Disability Unit (UPOH) of the Physical Medicine and Rehabilitation Department of our university hospital;
-
Admitted for the treatment of an osteomyelitis-associated pressure ulcer by surgical flap;
-
Having a neuromotor disability;
-
No opposition to be enrolled in the study from the patient, or from a legally authorized close relative if the patient's state of health does not allow it;
-
Affiliation to a social security scheme.
Exclusion Criteria:
- Under court protection.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Department of Physical Medicine and Rehabilitation, Raymond Poincaré Hospital, AP-HP | Garches | France | 92380 |
Sponsors and Collaborators
- Institut de Sante Parasport Connecte Synergies
- Assistance Publique - Hôpitaux de Paris
Investigators
- Principal Investigator: François Genêt, MD-PhD, Department of Physical Medicine and Rehabilitation, Raymond Poincaré Hospital, AP-HP, 92380 Garches, France
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2023-001